ARCA biopharma, Inc. (ABIO): Price and Financial Metrics
ABIO Price/Volume Stats
| Current price | $2.40 | 52-week high | $4.49 |
| Prev. close | $2.50 | 52-week low | $1.56 |
| Day low | $2.22 | Volume | 290,800 |
| Day high | $2.47 | Avg. volume | 607,995 |
| 50-day MA | $3.29 | Dividend yield | N/A |
| 200-day MA | $2.56 | Market Cap | 34.82M |
ABIO Stock Price Chart Interactive Chart >
ARCA biopharma, Inc. (ABIO) Company Bio
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
ABIO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -27.93% |
| 3-year | 4.35% |
| 5-year | -36.84% |
| YTD | N/A |
| 2024 | 0.00% |
| 2023 | -28.27% |
| 2022 | 10.23% |
| 2021 | -46.38% |
| 2020 | -29.78% |
Loading social stream, please wait...